CN102647908B - 组合 - Google Patents

组合 Download PDF

Info

Publication number
CN102647908B
CN102647908B CN201080055874.7A CN201080055874A CN102647908B CN 102647908 B CN102647908 B CN 102647908B CN 201080055874 A CN201080055874 A CN 201080055874A CN 102647908 B CN102647908 B CN 102647908B
Authority
CN
China
Prior art keywords
administration
days
compd
suitably
continuous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080055874.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN102647908A (zh
Inventor
M.邓布尔
T.吉尔默
R.库马
S.拉奎尔
P.F.勒博维茨
S.R.莫里斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Novartis Pharma AG
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of CN102647908A publication Critical patent/CN102647908A/zh
Application granted granted Critical
Publication of CN102647908B publication Critical patent/CN102647908B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201080055874.7A 2009-10-08 2010-10-08 组合 Expired - Fee Related CN102647908B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24980809P 2009-10-08 2009-10-08
US61/249,808 2009-10-08
PCT/US2010/051909 WO2011044415A1 (en) 2009-10-08 2010-10-08 Combination

Publications (2)

Publication Number Publication Date
CN102647908A CN102647908A (zh) 2012-08-22
CN102647908B true CN102647908B (zh) 2014-02-19

Family

ID=43857163

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080055874.7A Expired - Fee Related CN102647908B (zh) 2009-10-08 2010-10-08 组合

Country Status (14)

Country Link
US (1) US8796298B2 (ko)
EP (1) EP2485594B1 (ko)
JP (1) JP5881607B2 (ko)
KR (1) KR101696003B1 (ko)
CN (1) CN102647908B (ko)
AU (1) AU2010303364B2 (ko)
BR (1) BR112012008274A2 (ko)
CA (1) CA2777087C (ko)
EA (1) EA023018B1 (ko)
ES (1) ES2530436T3 (ko)
IL (1) IL219000A (ko)
MX (1) MX2012004140A (ko)
WO (1) WO2011044415A1 (ko)
ZA (1) ZA201202495B (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6100700B2 (ja) 2011-01-11 2017-03-22 ノバルティス アーゲー 組合せ
CN104540822B (zh) * 2013-07-08 2016-08-31 杭州普晒医药科技有限公司 达拉菲尼甲磺酸盐的晶型及其制备方法
CN107949642B (zh) * 2015-05-27 2022-04-26 奎斯特诊断投资股份有限公司 用于筛选实体瘤的组合物和方法
WO2020055760A1 (en) * 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9916885A (pt) 1999-01-13 2001-11-20 Warner Lambert Co Derivados de benzeno-sulfonamida e seu uso comoinibidores da mek
WO2004080972A1 (en) * 2003-03-12 2004-09-23 Vertex Pharmaceuticals Incorporated Pirazole modulators of atp-binding cassette transporters
US7514566B2 (en) * 2006-01-18 2009-04-07 Amgen, Inc. Thiazole compounds and methods of use
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds

Also Published As

Publication number Publication date
ZA201202495B (en) 2013-01-30
BR112012008274A2 (pt) 2015-09-22
JP5881607B2 (ja) 2016-03-09
EP2485594A4 (en) 2013-02-13
JP2013507383A (ja) 2013-03-04
CN102647908A (zh) 2012-08-22
US20120202835A1 (en) 2012-08-09
EA201270527A1 (ru) 2012-12-28
IL219000A (en) 2015-02-26
KR101696003B1 (ko) 2017-01-13
AU2010303364B2 (en) 2013-09-19
KR20120093931A (ko) 2012-08-23
ES2530436T3 (es) 2015-03-02
CA2777087C (en) 2017-10-31
EP2485594A1 (en) 2012-08-15
CA2777087A1 (en) 2011-04-14
MX2012004140A (es) 2012-09-07
EA023018B1 (ru) 2016-04-29
AU2010303364A1 (en) 2012-04-26
IL219000A0 (en) 2012-06-28
WO2011044415A1 (en) 2011-04-14
EP2485594B1 (en) 2015-01-07
US8796298B2 (en) 2014-08-05

Similar Documents

Publication Publication Date Title
AU2012205601B2 (en) Combination
CN102665418B (zh) 组合
CN102647908B (zh) 组合
EP2572199B1 (en) Combination
US20150094283A1 (en) Combination
US20150272950A1 (en) Combination
EP2908815A1 (en) Combination

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20151119

Address after: Basel, Switzerland

Patentee after: NOVARTIS AG

Address before: Basel, Switzerland

Patentee before: NOVARTIS PHARMA AG

Effective date of registration: 20151119

Address after: Basel, Switzerland

Patentee after: NOVARTIS PHARMA AG

Address before: American Pennsylvania

Patentee before: GLAXOSMITHKLINE LLC

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140219

Termination date: 20191008

CF01 Termination of patent right due to non-payment of annual fee